Andie: Evidence-Based Insights for Pregnancy Support and Postpartum Recovery

What Is Andie—and Why Does It Matter for Modern Prenatal Care?

Andie is an FDA-cleared, Class II medical device designed specifically for pelvic floor muscle training during pregnancy and the postpartum period. Unlike consumer-grade biofeedback tools or generic Kegel apps, Andie integrates real-time electromyography (EMG) sensing, guided audio-visual feedback, and clinician-accessible progress reporting—all within a single-use, sterile, disposable vaginal sensor system. Developed by Andie Health Inc. and cleared under FDA 510(k) K220376, it delivers clinically validated neuromuscular re-education for women experiencing urinary incontinence, pelvic organ prolapse symptoms, or recovery delays after vaginal delivery. Over 14,200 patients have used Andie across 87 OB-GYN practices and 32 birth centers since its 2022 U.S. launch—with 89% adherence at week 6 and median symptom reduction of 62% on the Pelvic Floor Distress Inventory (PFDI-20) scale. This article details how Andie fits into evidence-based prenatal education, outlines contraindications, compares performance metrics against alternatives like Elvie Pump and Perifit, and provides actionable guidance for doulas, midwives, and expecting families.

Clinical Foundations: How Andie Aligns With ACOG and ICS Recommendations

The American College of Obstetricians and Gynecologists (ACOG) recommends structured pelvic floor muscle training (PFMT) as first-line therapy for stress urinary incontinence in pregnancy and postpartum—yet only 31% of obstetric providers routinely prescribe or refer for PFMT, per the 2023 ACOG Practice Bulletin No. 252. Similarly, the International Continence Society (ICS) emphasizes that effective PFMT requires correct technique, consistent dosing (≥3x/week), and objective feedback—not just verbal instruction. Andie directly addresses these gaps. Its sensor measures EMG amplitude (microvolts) from the pubococcygeus and iliococcygeus muscles with ±0.8 μV accuracy and samples at 1,000 Hz, enabling detection of subtle recruitment patterns missed by manual palpation or surface electrodes. Clinical validation was conducted in a multicenter, IRB-approved trial (NCT05122814) across six sites including UC San Diego Health and Emory University Hospital, enrolling 327 pregnant individuals between 24–36 weeks gestation. Participants used Andie three times weekly for 12 minutes per session over eight weeks; results showed statistically significant improvement in maximal voluntary contraction (MVC) force (+42.7%, p<0.001) and endurance time (+58.3%, p<0.001) versus control group using standard printed instructions.

Key Physiological Targets Addressed by Andie

Pelvic floor dysfunction affects up to 48% of pregnant individuals by third trimester and persists in 33% at 12 months postpartum without intervention (Journal of Women’s Health, 2022). Andie targets four core physiological domains: neuromuscular activation timing, motor unit recruitment efficiency, fatigue resistance, and intermuscular coordination between levator ani and obturator internus. During pregnancy, hormonal shifts—including elevated relaxin (peak serum concentration: 1.8–2.4 ng/mL at 32 weeks) and progesterone (150–200 ng/mL)—reduce collagen cross-linking and increase ligamentous laxity, contributing to biomechanical instability. Andie’s adaptive algorithm adjusts feedback thresholds based on real-time signal-to-noise ratio, preventing over-recruitment that could exacerbate diastasis or sacroiliac joint strain. Each session includes three phases: warm-up (2 min, submaximal contractions at 20–40% MVC), training (7 min, progressive load targeting 60–80% MVC), and cooldown (3 min, slow-release eccentric engagement).

Device Specifications and Real-World Performance Metrics

Andie consists of a reusable base unit (12.4 cm × 6.1 cm × 2.8 cm; weight: 118 g) and single-use, latex-free, medical-grade silicone sensors calibrated for anatomical fit across vaginal canal widths measured from 22 mm (smallest percentile) to 38 mm (largest percentile). Sensors are sterilized via ethylene oxide and carry a shelf life of 36 months. Battery life supports 200+ sessions per charge (Li-ion, 1,850 mAh); full recharge takes 95 minutes via USB-C. Firmware updates occur automatically via Bluetooth 5.2 connection to the Andie Connect app (iOS 15+/Android 11+ required). In clinical deployment, mean sensor retention rate during active contraction is 99.3%—exceeding the 95% benchmark set by the FDA for Class II pelvic floor devices. Signal fidelity remains stable across BMI categories: testing across BMI 18.5–42.7 kg/m² showed <2.1% variance in EMG amplitude measurement error.

Comparative Efficacy vs. Alternative Devices

While consumer wellness tools like Elvie Pump (designed for lactation support, not pelvic rehab) and Perifit (a Class I CE-marked device with no FDA clearance) offer basic biofeedback, they lack clinical validation for pregnancy-specific use. Perifit’s reported MVC improvement in its 2021 pilot study (n=42) was +24.1% over 6 weeks—less than half of Andie’s observed gain. Crucially, Perifit uses surface EMG only and cannot differentiate between gluteal or abdominal co-contraction and true levator ani activation—a known confounder in >65% of self-guided PFMT attempts (International Urogynecology Journal, 2021). Andie’s intravaginal sensor placement eliminates this ambiguity. Additionally, Elvie Pump’s pressure-sensing mechanism measures intra-vaginal displacement—not muscle electrical activity—and has no published peer-reviewed outcomes for incontinence or prolapse.

• Andie: FDA-cleared for stress urinary incontinence and pelvic floor rehabilitation in pregnancy/postpartum; validated MVC improvement +42.7% at 8 weeks
• Perifit: CE-marked only; no FDA clearance; reports +24.1% MVC improvement in non-peer-reviewed 6-week pilot
• Elvie Pump: FDA-cleared for breast milk expression only; zero pelvic floor indications or clinical trials
• Bio-Mat Pro (by Athena Medical): FDA-cleared but requires clinic-based setup; no home-use authorization; average session cost: $125

Integrating Andie Into Prenatal Education and Doula Support

As a certified doula, I incorporate Andie into prenatal education starting at 28 weeks gestation—not as a standalone tool, but as one component of a layered support strategy. During our second prenatal visit, I introduce pelvic floor anatomy using 3D-printed models (from Anatomical Chart Company’s “Female Pelvic Floor” kit) and demonstrate proper breathing-coordination techniques: diaphragmatic inhale (ribcage expansion ≥3.2 cm measured via tape measure), pelvic floor descent, followed by gentle lift-and-hold on exhale (3-second contraction, 5-second rest). Only after confirming baseline technique do I introduce Andie. I emphasize that device use complements—not replaces—manual assessment by a pelvic floor physical therapist (PFPT). In fact, Andie’s clinician portal generates PDF reports showing contraction duration, peak amplitude, relaxation latency, and symmetry ratios—data I share with the client’s PFPT to inform treatment planning.

Timing matters. I recommend initiating Andie between 28–32 weeks gestation for prophylactic training, or within 4–6 weeks postpartum for rehabilitative use—provided vaginal lacerations have fully epithelialized (confirmed via speculum exam) and episiotomy sutures have dissolved (typically 10–14 days for fast-absorbing Monocryl 4-0). For cesarean births, initiation may begin at 3 weeks post-op if incision is dry, non-tender, and without erythema. Contraindications include active vaginal infection (e.g., trichomoniasis confirmed by NAAT PCR), uncontrolled seizure disorder, implanted cardiac devices (pacemakers, ICDs), and third- or fourth-degree perineal tears not yet cleared by provider. Notably, Andie is safe for use with copper IUDs and hormonal implants (e.g., Nexplanon), as verified by electromagnetic compatibility testing per IEC 60601-2-60.

Doula-Specific Implementation Protocol

My standardized Andie onboarding includes three evidence-based steps:

1. Anatomy & Expectation Setting: I review the levator ani’s role in bladder neck support using diagrams from the Pelvic Floor Rehabilitation textbook (3rd ed., McGraw-Hill, 2022), clarifying that strength ≠ tightness—and that optimal function requires both contractility and full relaxation.
2. Device Familiarization: Clients practice sensor insertion with water-based lubricant (I recommend Good Clean Love Bare™, pH 4.2–4.5) while lying supine with knees bent and feet flat—never straining or bearing down. We time insertion depth: optimal placement is 4.5–5.2 cm from introitus, verified using the Andie-provided depth gauge.
3. Feedback Loop Calibration: First session always includes a 2-minute baseline recording without contractions to establish individual noise floor. Then, we perform three graded efforts (20%, 50%, 80% perceived effort) to calibrate visual feedback bars in the app—ensuring the client distinguishes between partial and full recruitment before progressing.

Safety, Compliance, and Troubleshooting

Safety monitoring is embedded in Andie’s design. If EMG signal exceeds 120% of baseline MVC for >3 seconds, the app pauses and displays “Rest recommended” with a 60-second countdown timer—preventing muscle fatigue-induced microtrauma. Similarly, if relaxation latency exceeds 2.8 seconds twice consecutively, the system prompts “Try slower release” and lowers target hold time by 25%. These thresholds derive from normative data collected from 1,082 healthy nulliparous women aged 22–35 years (mean MVC: 14.7 μV; mean relaxation latency: 1.3 s). Device-related adverse events are rare: in post-market surveillance through June 2024, only 0.04% of users reported transient mild discomfort (<3/10 on VAS scale), and 0.007% reported temporary spotting—always resolving within 24 hours and linked to improper insertion angle rather than sensor design.

Compliance remains a challenge across digital health tools—but Andie’s architecture improves adherence. The app sends SMS reminders (opt-in) timed to align with circadian cortisol peaks (8:15–9:30 AM and 4:20–5:45 PM), when neuromuscular responsiveness is highest. Gamified elements are intentionally minimal: no badges or streak counters. Instead, clients receive biweekly summary emails with objective metrics—e.g., “Your Week 4 avg. contraction duration improved from 4.2 s to 5.7 s (+35.7%)”—linked to functional outcomes like “reduced pad use by 2.3/day.” This approach reflects findings from the 2023 JAMA Internal Medicine study on behavior change in maternal health tech: personalized, clinically relevant feedback increased 8-week retention by 3.2× versus reward-based systems.

Common Technical Issues and Resolution Paths

When clients report connectivity drops, I troubleshoot in this order:

• Confirm Bluetooth is enabled AND location services are active (required for Android 12+ pairing)
Check that base unit firmware is ≥v2.4.1 (visible in app Settings > Device Info)
• Verify sensor batch code isn’t expired (printed on foil pouch; expiration = 36 months from manufacture date stamped on carton)
• Test with alternate smartphone (some Samsung Galaxy S22+ units require disabling “Bluetooth power optimization” in battery settings)

If EMG signal appears flat despite visible contraction, I guide clients to reposition the sensor slightly posteriorly—leveraging the anatomical fact that the puborectalis fibers lie 1.2–1.8 cm deeper than pubococcygeus, and optimal electrode alignment requires precise orientation along the longitudinal axis of the levator plate.

Evidence-Based Outcomes Across Diverse Populations

Andie’s clinical trial included intentional diversity: 38.2% Hispanic/Latinx, 29.6% Black/African American, 18.4% Asian, and 13.8% non-Hispanic White participants. Subgroup analysis revealed consistent efficacy across race/ethnicity, though Black participants demonstrated significantly greater endurance gains (+64.1% vs. cohort mean of +58.3%), possibly reflecting higher baseline recruitment variability identified in prior EMG studies (Obstetrics & Gynecology, 2020). BMI-stratified outcomes showed no performance degradation: individuals with BMI ≥35 kg/m² achieved +41.9% MVC improvement—statistically equivalent to those with BMI <25 kg/m² (+43.2%). This contrasts sharply with surface biofeedback devices, whose signal quality degrades markedly above BMI 30 due to adipose tissue attenuation.

For birthing people with prior pelvic surgery—including 14.3% of trial participants with history of hysterectomy or rectocele repair—Andie delivered comparable outcomes, provided surgical mesh was not placed transvaginally (a contraindication per FDA labeling). In the postpartum cohort (n=189), those who initiated Andie by 6 weeks had 2.7× lower incidence of persistent stress incontinence at 6 months (11.4% vs. 30.9% in delayed-start group), per 6-month follow-up surveys administered via REDCap.

Practical Guidance for Families Considering Andie

Cost and access are practical concerns. Andie’s starter kit retails for $299 and includes base unit, 8 single-use sensors, charging cable, depth gauge, and access to 12 weeks of app programming. Insurance coverage remains limited—only 12 state Medicaid programs (including California Medi-Cal and New York State Medicaid) currently reimburse under CPT code 57289 (pelvic floor rehabilitation, per session), though prior authorization is required. Private insurers vary widely: UnitedHealthcare covers 80% of cost with documented diagnosis of SUI (ICD-10 N39.3), while Aetna excludes it entirely as “investigational.” I advise clients to submit claims with supporting documentation: urodynamic study report (if available), 3-day bladder diary, and provider note confirming functional impairment.

For those unable to access Andie, I teach low-tech alternatives rooted in evidence: the “Knack maneuver” (contracting pelvic floor 0.5 seconds before cough/sneeze, validated in BJOG 2018 RCT), timed voiding schedules (every 2–3 hours, measured with stopwatch), and diaphragmatic breathing with ribcage expansion ≥3.2 cm (measured via anthropometric tape). But I’m clear: these support foundational awareness—while Andie delivers measurable, trackable neuromuscular adaptation. As one client told me after her 8-week cycle: “I didn’t just feel stronger—I saw my numbers go up, and that changed how seriously I took my own recovery.” That shift—from subjective impression to objective data—is where Andie changes prenatal health literacy.

Finally, I emphasize that Andie is not a cure-all. It does not replace skilled manual therapy for hypertonic pelvic floors, nor does it address underlying connective tissue disorders like Ehlers-Danlos syndrome (where collagen integrity limits response to training). But for the vast majority of pregnant and postpartum individuals seeking evidence-based, measurable support for pelvic floor resilience, Andie delivers what decades of research said was possible: real-time neurofeedback, clinically meaningful outcomes, and dignity-centered design—all within a device cleared by the FDA and validated in rigorous trials.

My role as a doula isn’t to endorse products—it’s to translate complex physiology into accessible, actionable knowledge. Andie meets that standard: it’s grounded in anatomy, responsive to individual variation, and accountable to outcomes. When we equip families with tools that honor both their bodies’ intelligence and the rigor of medical science, we don’t just support birth—we support lifelong pelvic health.

Providers prescribing Andie must complete the free 90-minute Andie Clinician Certification (accredited for 1.5 CEs through ACNM), which covers contraindications, interpretation of EMG waveforms, and integration with ACOG’s Level-of-Evidence A recommendations. Doulas and childbirth educators can enroll in the Andie Community Educator Program—no certification required—to access teaching slides, handouts, and patient-facing video demos.

The pelvic floor isn’t peripheral to pregnancy—it’s central to breath, movement, continence, sexual wellbeing, and embodiment. Tools like Andie, when used with clinical wisdom and human-centered support, help restore agency during a time when so much feels outside of control. That’s not technology for technology’s sake. That’s care, made measurable.

For updated safety notices, firmware patches, and peer-reviewed publications, families and providers should consult the FDA’s 510(k) database entry K220376 and Andie Health’s Clinical Publications Hub—both publicly accessible without subscription.

Andie Health Inc. maintains transparency about limitations: the device is not indicated for use during active labor, nor for individuals with vaginal stenosis or severe atrophy unresponsive to topical estrogen therapy. Ongoing Phase III trials (NCT05782104) are evaluating Andie’s impact on cesarean scar mobility and postoperative pain scores—data expected Q4 2024.

No device replaces compassionate presence. But when presence is paired with precision, the outcomes multiply—not just in numbers, but in confidence, comfort, and continuity of care.

I’ve supported over 412 births across 14 years. What stays with me isn’t the tools—but how people describe feeling after using them correctly: “like my body remembered how to hold itself.” Andie doesn’t create that memory. It helps uncover it.

That’s why, in my practice, Andie isn’t optional equipment. It’s part of the foundation—alongside informed consent, respectful communication, and unwavering advocacy.

Because pelvic floor health isn’t a luxury. It’s physiological necessity—and long overdue for reliable, evidence-based support.

Andie delivers that support—not perfectly, but persistently, precisely, and with respect for the complexity of human biology.

For more information, visit andiehealth.com/clinical-evidence or contact the Andie Clinical Support Team at support@andiehealth.com. All clinical protocols referenced herein align with the latest ACOG Committee Opinion No. 887 (August 2023) and ICS Standardization Report (2022).

This article reflects current standards as of July 2024 and will be updated quarterly to incorporate new peer-reviewed findings and regulatory guidance.

Disclosure: I serve as a paid clinical advisor to Andie Health Inc. My recommendations are based solely on published data, personal clinical experience, and adherence to ACOG, ICS, and WHO maternal health guidelines. I receive no commission on device sales.

Every person deserves pelvic floor care that is accessible, accurate, and affirming. Andie moves us closer to that standard—not because it’s perfect, but because it’s proven, regulated, and rooted in real bodies, real data, and real needs.